26 February 2015
DETAILS
Fiscal 2014:
Bayer: strong business momentum continues and
portfolio transformation underway
Group portfolio to focus on Life Sciences
All subgroups contribute to record sales and earnings
Recently launched products drive growth momentum
Net income increases 7.4 percent to EUR 3,426 million
Core earnings per share up 7.3 percent to EUR 6.02
Cash Flow increases to EUR 5,810 up 12.4 percent
EBITDA before special items
up by 4.9 percent to EUR 8,812 million
EBIT advances by 11.6 percent to EUR 5,506 million
Group sales EUR 42,239 million
(plus 5.2 percent / Fx & portfolio adj. plus 7.2 percent)
Forecast for 2015:
further sales growth and clear improvement in earnings
WWW.CHEMWINFO.COM BY KHUN PHICHAI
